İ. DOĞAN Et Al. , "Efficacy of the VIT (vincristine, irinotecan and temozolomide) regimen in adults with metastatic Ewing sarcoma," JOURNAL OF CHEMOTHERAPY , vol.35, no.4, pp.343-347, 2023
DOĞAN, İ. Et Al. 2023. Efficacy of the VIT (vincristine, irinotecan and temozolomide) regimen in adults with metastatic Ewing sarcoma. JOURNAL OF CHEMOTHERAPY , vol.35, no.4 , 343-347.
DOĞAN, İ., Iribas, A., Ahmed, M. A., & Basaran, M., (2023). Efficacy of the VIT (vincristine, irinotecan and temozolomide) regimen in adults with metastatic Ewing sarcoma. JOURNAL OF CHEMOTHERAPY , vol.35, no.4, 343-347.
DOĞAN, İzzet Et Al. "Efficacy of the VIT (vincristine, irinotecan and temozolomide) regimen in adults with metastatic Ewing sarcoma," JOURNAL OF CHEMOTHERAPY , vol.35, no.4, 343-347, 2023
DOĞAN, İzzet Et Al. "Efficacy of the VIT (vincristine, irinotecan and temozolomide) regimen in adults with metastatic Ewing sarcoma." JOURNAL OF CHEMOTHERAPY , vol.35, no.4, pp.343-347, 2023
DOĞAN, İ. Et Al. (2023) . "Efficacy of the VIT (vincristine, irinotecan and temozolomide) regimen in adults with metastatic Ewing sarcoma." JOURNAL OF CHEMOTHERAPY , vol.35, no.4, pp.343-347.
@article{article, author={İzzet DOĞAN Et Al. }, title={Efficacy of the VIT (vincristine, irinotecan and temozolomide) regimen in adults with metastatic Ewing sarcoma}, journal={JOURNAL OF CHEMOTHERAPY}, year=2023, pages={343-347} }